Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
1000 participants
OBSERVATIONAL
2021-10-15
2028-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biomarker-based Exclusion of VAP for Improved Antibiotic Stewardship
NCT01972425
Biomarker Guided Antibiotic Treatment in Community-Acquired Pneumonia
NCT03146182
Diagnostic Accuracy of Infection Biomarkers in the Initial Investigation of Patients With Suspected Pneumonia
NCT04652167
Diagnostic Breath Analysis for Detection of Ventilator Acquired Pneumonia (VAP)
NCT03053258
Ventilator-associated Pneumonia (VAP) Diagnostic Stewardship Trial
NCT05176353
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
VAP
Enrolled participants that fully meet the criteria of VAP.
Heparin-binding protein
Evaluation of the specificity and sensitivity of HBP as diagnostic biomarker for VAP.
Interleukin-26
Evaluation of the specificity and sensitivity of IL-26 as diagnostic biomarker for VAP.
Microbiome
Evaluation of the specificity and sensitivity of the lung microbiome as prognostic biomarker for VAP.
Bacterial transcriptome
Evaluation of the specificity and sensitivity of the bacterial transcriptome as prognostic biomarker for treatment failure of VAP.
Proteome
Evaluation of the specificity and sensitivity of the proteome in mini-BAL as biomarker for VAP.
Suspect VAP
Enrolled participants that develop signs of VAP but lack some variable, for instace new radiographic infiltrate or microbiological finding compatible with VAP.
Heparin-binding protein
Evaluation of the specificity and sensitivity of HBP as diagnostic biomarker for VAP.
Interleukin-26
Evaluation of the specificity and sensitivity of IL-26 as diagnostic biomarker for VAP.
Microbiome
Evaluation of the specificity and sensitivity of the lung microbiome as prognostic biomarker for VAP.
Proteome
Evaluation of the specificity and sensitivity of the proteome in mini-BAL as biomarker for VAP.
No VAP
Enrolled participants that do not develop VAP.
Heparin-binding protein
Evaluation of the specificity and sensitivity of HBP as diagnostic biomarker for VAP.
Interleukin-26
Evaluation of the specificity and sensitivity of IL-26 as diagnostic biomarker for VAP.
Microbiome
Evaluation of the specificity and sensitivity of the lung microbiome as prognostic biomarker for VAP.
Proteome
Evaluation of the specificity and sensitivity of the proteome in mini-BAL as biomarker for VAP.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Heparin-binding protein
Evaluation of the specificity and sensitivity of HBP as diagnostic biomarker for VAP.
Interleukin-26
Evaluation of the specificity and sensitivity of IL-26 as diagnostic biomarker for VAP.
Microbiome
Evaluation of the specificity and sensitivity of the lung microbiome as prognostic biomarker for VAP.
Bacterial transcriptome
Evaluation of the specificity and sensitivity of the bacterial transcriptome as prognostic biomarker for treatment failure of VAP.
Proteome
Evaluation of the specificity and sensitivity of the proteome in mini-BAL as biomarker for VAP.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Intubation within last 24 hours
* Anticipated mechanical ventilation of at least 48 hours
Exclusion Criteria
* Ongoing infection of the lungs at admission to the ICU.
* Severely elevated or instable intracranial pressure.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lund University
OTHER
Region Skane
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Magnus Paulsson, PhD MD
Role: PRINCIPAL_INVESTIGATOR
Skane University Hospital
Fredrik Sjövall, PhD MD
Role: STUDY_CHAIR
Skane University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vestre Viken
Drammen, , Norway
Hospital de São Francisco Xavier
Lisbon, , Portugal
Skåne University Hospital, Dept. of Infectious diseases
Lund, , Sweden
Skåne university Hospital, ICU
Malmo, , Sweden
Karolinska University Hospital, ICU
Solna, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Fredrik Sjövall, PhD MD
Role: primary
Johan Petersson, PhD MD
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Paulsson M, Cardenas EI, Che KF, Brundin B, Smith M, Qvarfordt I, Linden A. TLR4-mediated release of heparin-binding protein in human airways: a co-stimulatory role for IL-26. Front Immunol. 2023 May 10;14:1178135. doi: 10.3389/fimmu.2023.1178135. eCollection 2023.
Paulsson M, Thelaus L, Riesbeck K, Qvarfordt I, Smith ME, Linden A, Linder A. Heparin-binding protein in lower airway samples as a biomarker for pneumonia. Respir Res. 2021 Jun 8;22(1):174. doi: 10.1186/s12931-021-01764-2.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-00219
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.